Select your country or region to view content specific to your country.
Jul 22, 2011
Seegene announces a new concept of Real-time multiplex diagnostic technology
TOCE™ technology provides a new concept of melting curve analysis enhanced multiplexing, improved flexibility in probe design and cross-platform compatibility
ROCKVILLE, Maryland and SEOUL, Korea, July 20, 2011 ? Seegene today announced that it will unveil TOCE™, a new platform technology for real-time PCR, at the 2011 Clinical Lab Expo of the American Association for Clinical Chemistry (AACC), booth #1653.
TOCE™ is a novel technology for melting curve analysis. The method is readily utilizable for organism identification and the detection of mutations in clinical samples. Until now, melting curve analysis has been constrained by several inherent limitations ? namely, constrained probe design, the inability to extensively and efficiently multiplex, and high sensitivity of the melting curves (Tm) due to sequence variation of the probe site.
TOCE™ technology overcomes these limitations, providing:
Dr. Jong-Yoon Chun, Chief Executive Officer of Seegene, said, “TOCE™ technology will open new opportunities for detecting different, and more types of infectious diseases, such as MTB, respiratory infections, and STIs, and genetic mutations. Furthermore, it will enable multiplex real-time PCR to be more widely used in molecular diagnostics.”
Seegene will begin introducing TOCE™ in its lineup of multiplex diagnostic tests. The first application of TOCE™ will be a respiratory test that simultaneously detects 16 respiratory viruses and 5 pneumonic bacteria, and a test for sexually transmitted infections (STIs) that simultaneously detects 7 pathogens.
Seegene, Inc. is a leading molecular diagnostics company developing, manufacturing and marketing innovative “multiplex” (or “multi-pathogen detection”) molecular diagnostic products and services. It holds proprietary technologies of both PCR and Real-time PCR named ACP™, DPO™, and READ, which sets a standard in high-throughput and simultaneous multi-pathogen detection called “multiplex PCR.” The novel multiplex Real-time PCR technology, READ, overcomes the limitations of conventional Real-time PCR, providing dramatic improvement in sensitivity and specificity. Seegene holds three novel Molecular diagnostic platforms: Seeplex® system adapting DPO™ Technology, Anyplex™ and Magicplex™ system which are Real-time PCR detection platform adapting DPO™ and READ Technology. Seegene’s products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene’s mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.
For more information please visit www.seegene.comor call +301-762-9066.
Seegene Introduces Anyplex™ Plus Test, a total solution for diagnosing Tuberculosis AnyplexTM Plus multiplex diagnostic test simultaneously identifies TB, multi-drug resistant TB and extensively multi-drug resistant TB ROCKVILLE, Maryland and SEOUL, Korea, July ...